Navigation Links
Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
Date:11/8/2011

MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq:  ALXA) today announced that it is presenting at the 24th Annual U.S. Psychiatric and Mental Health Congress, being held November 7 - 10, 2011.  The abstract and poster presentation, entitled "Treating Agitation with Inhaled Loxapine (AZ-004): Responder Analyses in Patients with Schizophrenia or Bipolar Disorder", is being presented today by Dr. James V. Cassella, Alexza's Senior Vice President of Research and Development.  Alexza has previously reported and presented the primary findings of its two Phase 3 clinical trials with Staccato loxapine.  In this presentation, Alexza is presenting additional analyses of these data, using two different responder methodologies.

Methodologies

The efficacy of Staccato loxapine in treating agitation was measured using the PANSS-Excited Component (PEC) and Clinical Global Impression - Improvement (CGI-I) scales in two Phase 3 randomized, double-blind, placebo-controlled trials in agitated patients with schizophrenia (n=344) or bipolar I disorder (n=314).  At the beginning of the treatment period, patients received a single inhalation of either 0mg (placebo), 5mg or 10mg of Staccato loxapine.  The primary endpoint was successfully achieved in both studies and has been previously reported and published.  As a further efficacy assessment, two responder analyses, PEC40 and CGI-Improvement, were conducted with responders defined as: (1) patients with a >40% decrease from baseline in the total PEC score (starting at 10 minutes post-dose); and (2) patients rated as "much improved" or "very much improved" on the CGI-I scale (assessed at 2 hours post-dose).  Responder analyses are important as they are a method to determine the magnitude of clinical relevance of patient response to a treatment.

PEC40 Responders Analysis

In agitated patients with schizophreni
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" ... analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in ... Vials, and IV solutions), Solid Dosage Forms (Tablets and ... Gels, Creams & Ointments). The report provides ...
(Date:8/19/2014)... 2014  AVIA – a provider-led accelerator that puts ... problems in healthcare ­– announces Sutter Health, a not-for-profit ... as the most recent addition to the AVIA Innovator ... AVIA,s inaugural cohort focused helping patients navigate the healthcare ... a patient,s providers so they work as a larger ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... measurement technology, today announced the addition of the EmBand 24™ to the EmBand™ family of neuromarketing measurement devices. , ... , , ... ... ...
... , ATLANTA , March 22 Fulcrum Ventures announced today that they invested $1.25 ... solution for kit design, production, client supply management and patient specimen tracking.  Based in Columbus, Georgia , ... ... , ...
Cached Medicine Technology:EmSense Announces Release of Revolutionary EmBand 24(TM) 2EmSense Announces Release of Revolutionary EmBand 24(TM) 3EmSense Announces Release of Revolutionary EmBand 24(TM) 4Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 2Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 3
(Date:8/20/2014)... Rockville Centre, NY (PRWEB) August 20, 2014 ... Martinotti and filed on August 7 in the multicounty ... New Jersey (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; ... in the MCL have been dismissed without prejudice. The ... “in the process of being resolved.” The Rottenstein Law ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... One Call Alert expands its line of personal ... fully-mobile wearable device that connects customers to the help they ... a day, 365 days a year. , ResCube can go ... operates on the T-Mobile nationwide network like a cell phone, ... , Like with the other One Call Alert systems, ResCube ...
(Date:8/20/2014)... Auckland suggest that both major forms of diabetes are the ... today in the FASEB Journal (20 August), provide ... are both caused by the formation of toxic clumps of ... on 20 years, work in New Zealand, suggest that type-1 ... reversed by medicines that stop amylin forming these toxic clumps. ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... May 21, 2012. West Orange, NJ. Scientists at ... studies in multiple sclerosis at the Hilton San Diego ... John DeLuca, Nancy Chiaravalloti and Yael Goverover are addressing ... Multiple Sclerosis Centers (CMSC) and the Americas Committee for ...
... peers and primary care office staff can help patients improve ... new drug, a new study found. Barbara J. Turner, M.D., ... senior author. The randomized, controlled trial examined whether six ... care office staff could benefit African-American patients who had ...
... 21 (HealthDay News) -- Heart damage can be present in obese ... preliminary study found. Obesity is a risk factor for heart ... to their hearts. In the new study, researchers examined the ... overweight and 32 obese -- with no symptoms of heart disease. ...
... General Hospital (MGH) surgeons have developed a new technique ... In the May Annals of Otology, Rhinology ... which uses cryopreserved aortas from deceased donors to replace ... permanent tracheotomy and maintain voice and swallowing function with ...
... May 21 (HealthDay News) -- Having so-called intensivist physicians on ... death rates in ICUs that do not have similar coverage ... An intensivist is a doctor who specializes in the care ... or co-manage patients during the day are referred to as ...
... Almost a century after telephone pioneer Alexander Graham ... vapor sensors ― "electronic noses" ― are being developed ... and other futuristic uses. A new episode in ... series takes viewers on a behind-the-science tour of ...
Cached Medicine News:Health News:Kessler Foundation scientists present cognitive research findings at MS dual symposium 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Obese Teens Can Have Heart Damage Without Showing Signs 2Health News:Donor aortic graft improves reconstruction after partial laryngectomy 2Health News:Night Staffing With Critical Care Docs May Lower ICU Death Rates 2